FI880428A0 - Ytantigener av hepatit b virus och hybridantigener innehaollande desamma. - Google Patents

Ytantigener av hepatit b virus och hybridantigener innehaollande desamma.

Info

Publication number
FI880428A0
FI880428A0 FI880428A FI880428A FI880428A0 FI 880428 A0 FI880428 A0 FI 880428A0 FI 880428 A FI880428 A FI 880428A FI 880428 A FI880428 A FI 880428A FI 880428 A0 FI880428 A0 FI 880428A0
Authority
FI
Finland
Prior art keywords
ytantigener
hybridantigener
hepatit
och
virus
Prior art date
Application number
FI880428A
Other languages
English (en)
Other versions
FI880428A (fi
Inventor
Teresa Cabezon
Wilde Michael De
Nigel Harford
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Publication of FI880428A0 publication Critical patent/FI880428A0/fi
Publication of FI880428A publication Critical patent/FI880428A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
FI880428A 1987-01-30 1988-01-29 Ytantigener av hepatit b virus och hybridantigener innehaollande desamma. FI880428A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US932587A 1987-01-30 1987-01-30

Publications (2)

Publication Number Publication Date
FI880428A0 true FI880428A0 (fi) 1988-01-29
FI880428A FI880428A (fi) 1988-09-13

Family

ID=21736956

Family Applications (1)

Application Number Title Priority Date Filing Date
FI880428A FI880428A (fi) 1987-01-30 1988-01-29 Ytantigener av hepatit b virus och hybridantigener innehaollande desamma.

Country Status (20)

Country Link
EP (1) EP0278940A3 (fi)
JP (1) JPS6463382A (fi)
KR (1) KR880009130A (fi)
CN (1) CN1031395A (fi)
AP (1) AP56A (fi)
AU (1) AU1093088A (fi)
DD (3) DD285612A5 (fi)
DK (1) DK43188A (fi)
FI (1) FI880428A (fi)
HU (1) HUT50876A (fi)
IL (1) IL85216A0 (fi)
MA (1) MA21169A1 (fi)
NO (1) NO880395L (fi)
NZ (1) NZ223297A (fi)
OA (1) OA08801A (fi)
PT (1) PT86640B (fi)
SU (1) SU1746887A3 (fi)
TN (1) TNSN88004A1 (fi)
YU (1) YU17488A (fi)
ZA (1) ZA88488B (fi)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341074C (en) 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
EP0345792A3 (en) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag Htlv-i / hiv-1 fusion proteins
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5130247A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
US5130248A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAg
EP0421626A1 (en) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccine for aids and hepatitis B
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
AU2927892A (en) * 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
DE69231693T2 (de) * 1991-12-23 2001-05-31 Bayer Corp., East Walpole Hbv amplifizierungssonden zur verwendung in hybridisierungssandwichassay in der lösungsphase
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
KR20030096423A (ko) * 1992-03-06 2003-12-31 엔. 브이. 이노제네틱스 소시에떼아노님 면역학적으로 중요한 에피토프에 상응하는 펩티드의 측정방법 및 면역학적으로 중요한 에피토프에 상응하는 항체또는 비오티닐화된 펩티드의 측정 방법에 상기 펩티드를사용하는 방법, 상기 펩티드의 제조방법 및 상기 펩티드를함유하는 조성물
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
UA40596C2 (uk) 1992-05-23 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини та спосіб її одержання
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
EP2397852B1 (en) 2006-03-14 2013-12-04 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
WO2008028957A2 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
EP2125868B1 (en) 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
CN108289940B (zh) 2015-08-03 2023-01-13 美国卫生和人力服务部 Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) * 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
EP0174444B1 (en) * 1984-06-18 1992-03-11 Chiron Corporation Hepatitis surface antigen particle vaccine
EP0401941A3 (en) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Hepatitis b virus surface antigen and production thereof
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
JP2615027B2 (ja) * 1985-04-08 1997-05-28 アムジェン インコーポレイテッド 外来遺伝子の転写を制御するための方法及びハイブリッドプロモーター
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein

Also Published As

Publication number Publication date
YU17488A (en) 1991-02-28
NZ223297A (en) 1991-06-25
CN1031395A (zh) 1989-03-01
EP0278940A3 (en) 1988-12-07
AU1093088A (en) 1988-08-04
NO880395D0 (no) 1988-01-29
AP56A (en) 1989-09-26
PT86640B (pt) 1992-01-31
AP8800078A0 (en) 1987-11-01
NO880395L (no) 1988-08-01
JPS6463382A (en) 1989-03-09
OA08801A (fr) 1989-03-31
KR880009130A (ko) 1988-09-14
DD285612A5 (de) 1990-12-19
TNSN88004A1 (fr) 1990-07-10
MA21169A1 (fr) 1988-10-01
EP0278940A2 (en) 1988-08-17
IL85216A0 (en) 1988-07-31
DK43188D0 (da) 1988-01-28
SU1746887A3 (ru) 1992-07-07
DD285994A5 (de) 1991-01-10
FI880428A (fi) 1988-09-13
PT86640A (pt) 1988-02-01
HUT50876A (en) 1990-03-28
DD284899A5 (de) 1990-11-28
DK43188A (da) 1988-07-31
ZA88488B (en) 1988-10-26

Similar Documents

Publication Publication Date Title
FI880428A0 (fi) Ytantigener av hepatit b virus och hybridantigener innehaollande desamma.
FI870979A0 (fi) Filterkonstruktion och foerfarande foer bildande av filterkonstruktion.
FI871274A0 (fi) Foerfarande och anordning foer styrning av bergborrning.
FI87024B (fi) Foerfarande foer styrning av en kortsluten asynkronmotor och styrkrets.
FI872372A0 (fi) Foerfarande och anordning foer kapning av haolelement.
FI872419A0 (fi) Foerfarande och arrangemang foer effektivering av avgasernas utnyttjande.
FI870184A0 (fi) Akustiskt stroemningsmaetningsfoerfarande och anordning foer tillaempning av detta.
FI871739A (fi) Foerfarande och anordning foer aotskiljning av vaetskor.
FI872312A0 (fi) Foerfarande och anordning foer forskning av vaegbelaeggningars slitning.
FI872505A (fi) Foerfarande och anordning foer styrning av en lyftmotor.
FI80863B (fi) Foerfarande och anordning foer lagring av pappersrullar.
FI871323A0 (fi) Anordning foer avkvistning och kapning av stockar serievis.
FI871002A0 (fi) Foerfarande och anordning foer belaeggning av materialbana.
FI871241A (fi) Foerfarande foer framstaellning av vattentaet golvbelaeggning och vattentaet golvbelaeggning.
FI871256A0 (fi) Plattbalksystem av kontinuerlig betong och foerfarande foer bildande av detta.
FI870183A0 (fi) Foerfarande och anordning foer skalning av laongstraeckta oskalade stycken.
FI870124A0 (fi) Vaermeackumulator foer underlaettad kallstart och foervaermning av vaetskekylda fordon.
FI871306A (fi) Foerfarande och anordning foer fyllning och foerslutning av en flervaeggad ventilpaose.
FI870339A0 (fi) Brottsensor och foerfarande foer framstaellning av densamma.
FI871388A0 (fi) Foerfarande och anordning foer styrning av en vaexelstroemsmotor.
FI871391A0 (fi) Foerfarande foer reglering av en ventilationskanal och anordning foer foerfarandets genomfoerande.
FI871518A (fi) Syrakatalysatorer och anvaendning av dessa.
FI871020A0 (fi) Foerfarande och anordning foer uppsamling av olja.
FI871167A0 (fi) Poroest saeckpapper och foerfarande foer tillverkning av detsamma.
FI871968A0 (fi) Kombination av ventilationsventil och brandbegraensare.

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: SMITHKLINE BIOLOGICALS S.A.